Treg-Targeted IL-2/Anti-IL-2 Complex Controls Graft-Versus-Host Disease and Supports Anti-Tumor Effect in Allogeneic Hematopoietic Stem Cell Transplantation

In dedicated experimental models of allogeneic hematopoietic stem cell transplantation the authors evaluated side-by-side the therapeutic effect of two IL-2/anti-IL-2 complexes designed either to boost Tregs, or alternatively to activate effector T cells Teffs, on GVHD occurrence and tumor relapse.